Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Senior Vice President | May 25, 2010 | May 27, 2010 |
| BAXTER INTERNATIONAL INCBAX · Entity 1707 | Director | May 03, 2022 | May 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date May 25, 2010 · Filed May 27, 2010
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 99,279 |
Reported balance
After 2010-05-25 transaction · row 1
1 source rowRow 1 · 2010-05-25 · Gift · Disposed 555 · Balance 99,279 |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy daughter | 1,643 |
Reported balance
After 2010-05-25 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2010-05-25 · Gift · Acquired 555 · Balance 1,643 F2: The reporting person disclaims beneficial ownership of all securities held by his wife and daughter. |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 18,758 |
Reported balance
Holding disclosure · report date 2010-05-25 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 18,758 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of May 26, 2010. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy wife | 36,407 |
Reported balance
Holding disclosure · report date 2010-05-25 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 36,407 F2: The reporting person disclaims beneficial ownership of all securities held by his wife and daughter. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of May 26, 2010.
F2: The reporting person disclaims beneficial ownership of all securities held by his wife and daughter.
BAXTER INTERNATIONAL INC
Report date May 03, 2022 · Filed May 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $1 par valueSEC Table I · non-derivative | Direct | 15,740 |
Reported balance
After 2022-05-03 transaction · row 1
1 source rowRow 1 · 2022-05-03 · Grant · Acquired 2,706 · Balance 15,740 F1: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. |
| Common Stock, $1 par valueSEC Table I · non-derivative | IndirectShares Owned by Thomas F. Chen Grantor Irrevocable Trust | 9,174 |
Reported balance
Holding disclosure · report date 2022-05-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 9,174 |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
STERICYCLE INC
Report date November 04, 2024 · Filed November 04, 2024
Section 16 reporting ended · disclosed 2024-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-11-04 transaction · row 1
1 source rowRow 1 · 2024-11-04 · Disposition to issuer · Disposed 20,303 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of June 3, 2024 (the "Merger Agreement"), by and among Stericycle, Inc. (the "Company"), Waste Management, Inc. and Stag Merger Sub Inc., at the effective time (the "Effective Time") of the merger of Stag Merger Sub Inc. with and into the Company, which Effective Time occurred on November 4, 2024, each outstanding share of Company common stock was converted into the right to receive $62.00 per share in cash, without interest. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $138.45 · Expires 2025-05-27 | Direct | 0 |
Reported balance
After 2024-11-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-11-04 · Disposition to issuer · Disposed 4,931 · Balance 0 F2: This stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was fully vested and outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (without interest) an amount of cash equal to the product of (i) the number of shares underlying the stock option multiplied by (ii) the excess, if any, of $62.00 over the exercise price of such stock option. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $97.47 · Expires 2026-05-25 | Direct | 0 |
Reported balance
After 2024-11-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-11-04 · Disposition to issuer · Disposed 3,713 · Balance 0 F2: This stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was fully vested and outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (without interest) an amount of cash equal to the product of (i) the number of shares underlying the stock option multiplied by (ii) the excess, if any, of $62.00 over the exercise price of such stock option. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-11-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-11-04 · Disposition to issuer · Disposed 3,524 · Balance 0 F3: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock. F4: Represents RSUs that would have vested in full on the earlier of the one-year anniversary of the grant date or the date of the 2025 Annual Meeting of Stockholders, provided that the date of the 2025 Annual Meeting of Stockholders had been at least 50 weeks after the date of the 2024 Annual Meeting of Stockholders. Pursuant to the Merger Agreement, at the Effective Time, these RSUs were canceled and converted into the right to receive (without interest) an amount in cash equal to the number of RSUs multiplied by $62.00. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-11-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-11-04 · Disposition to issuer · Disposed 1,506 · Balance 0 F3: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock. F5: Represents RSUs that were fully vested prior to the Effective Time, but, in accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person previously elected to defer actual receipt of the shares to which such person would otherwise have been entitled upon vesting until such person's separation of service from the issuer. Pursuant to the Merger Agreement, at the Effective Time, these RSUs were canceled and converted into the right to receive (without interest) an amount in cash equal to the number of RSUs multiplied by $62.00. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of June 3, 2024 (the "Merger Agreement"), by and among Stericycle, Inc. (the "Company"), Waste Management, Inc. and Stag Merger Sub Inc., at the effective time (the "Effective Time") of the merger of Stag Merger Sub Inc. with and into the Company, which Effective Time occurred on November 4, 2024, each outstanding share of Company common stock was converted into the right to receive $62.00 per share in cash, without interest.
F2: This stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was fully vested and outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (without interest) an amount of cash equal to the product of (i) the number of shares underlying the stock option multiplied by (ii) the excess, if any, of $62.00 over the exercise price of such stock option.
F3: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock.
F4: Represents RSUs that would have vested in full on the earlier of the one-year anniversary of the grant date or the date of the 2025 Annual Meeting of Stockholders, provided that the date of the 2025 Annual Meeting of Stockholders had been at least 50 weeks after the date of the 2024 Annual Meeting of Stockholders. Pursuant to the Merger Agreement, at the Effective Time, these RSUs were canceled and converted into the right to receive (without interest) an amount in cash equal to the number of RSUs multiplied by $62.00.
F5: Represents RSUs that were fully vested prior to the Effective Time, but, in accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person previously elected to defer actual receipt of the shares to which such person would otherwise have been entitled upon vesting until such person's separation of service from the issuer. Pursuant to the Merger Agreement, at the Effective Time, these RSUs were canceled and converted into the right to receive (without interest) an amount in cash equal to the number of RSUs multiplied by $62.00.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2017 Filed May 12, 2017 19:58 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantDeferred Comp Plan Baxter Common Stock Fund · Derivative | 29 | $56.19 | $1,629.51 |
DisclosureSEC source: 0001360147-17-000003 · edgar.xml · derivative · entry 1 Chen Thomas F · CIK 0001360147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,815 Underlying: Common Stock, $1 par value · 29 shares Expires not disclosed F1 · derivative.exercise_price: 1 for 1 F2 · derivative.exercise_date: Reporting person allocated compensation deferred under Baxter's Deferred Compensation Plan (the "Plan") to the Baxter Common Stock Fund notional investment alternative. Reporting person's account balance is payable subject to the terms of the Plan. F2 · derivative.expiration_date: Reporting person allocated compensation deferred under Baxter's Deferred Compensation Plan (the "Plan") to the Baxter Common Stock Fund notional investment alternative. Reporting person's account balance is payable subject to the terms of the Plan. Read SEC document |
| May 02, 2017 Filed May 4, 2017 20:48 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 3,233 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001360147-17-000002 · edgar.xml · nonDerivative · entry 1 Chen Thomas F · CIK 0001360147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,216 F1 · price: The reporting person received a grant of 3,233 fully vested shares of common stock of Baxter International Inc. (the "Company"), subject to the terms and conditions of the applicable grant. Read SEC document |
| January 20, 2017 Filed Jan 23, 2017 21:25 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantDeferred Comp Plan Baxter Common Stock Fund · Derivative | 153 | $46.23 | $7,073.19 |
DisclosureSEC source: 0001360147-17-000001 · edgar.xml · derivative · entry 1 Chen Thomas F · CIK 0001360147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,810 Underlying: Common Stock, $1 par value · 153 shares Expires not disclosed F1 · derivative.exercise_price: 1 for 1 F2 · derivative.exercise_date: Reporting person allocated compensation deferred under Baxter's Non-Employee Director Deferred Compensation Plan to the Baxter Common Stock Fund notional investment alternative. F2 · derivative.expiration_date: Reporting person allocated compensation deferred under Baxter's Non-Employee Director Deferred Compensation Plan to the Baxter Common Stock Fund notional investment alternative. Read SEC document |
| October 21, 2016 Filed Oct 25, 2016 20:09 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantDeferred Comp Plan Baxter Common Stock Fund · Derivative | 147 | $48.18 | $7,082.46 |
DisclosureSEC source: 0001360147-16-000010 · edgar.xml · derivative · entry 1 Chen Thomas F · CIK 0001360147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,630 Underlying: Common Stock, $1 par value · 147 shares Expires not disclosed F1 · derivative.exercise_price: 1 for 1 F2 · derivative.exercise_date: Reporting person allocated compensation deferred under Baxter's Non-Employee Director Deferred Compensation Plan to the Baxter Common Stock Fund notional investment alternative. F2 · derivative.expiration_date: Reporting person allocated compensation deferred under Baxter's Non-Employee Director Deferred Compensation Plan to the Baxter Common Stock Fund notional investment alternative. Read SEC document |
| May 25, 2010 Filed May 27, 2010 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 555 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-009442 · edgar.xml · nonDerivative · entry 3 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 1,643 F2 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his wife and daughter. Read SEC document |
| May 25, 2010 Filed May 27, 2010 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 555 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-009442 · edgar.xml · nonDerivative · entry 1 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,279 Read SEC document |
| May 01, 2010 Filed May 4, 2010 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,156 | $51.16 | $161,460.96 |
DisclosureSEC source: 0001179110-10-007826 · edgar.xml · nonDerivative · entry 1 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,834 Read SEC document |
| March 18, 2010 Filed Apr 9, 2010 21:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 12,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-006815 · edgar.xml · nonDerivative · entry 3 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 36,407 F2 · balance_after: Reporting person disclaims beneficial ownership of all securities held by his wife and daughter. Read SEC document |
| March 18, 2010 Filed Apr 9, 2010 21:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 12,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-006815 · edgar.xml · nonDerivative · entry 1 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,990 Read SEC document |
| March 01, 2010 Filed Mar 2, 2010 23:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 1,855 | $0.00 Strike: $54.28 | $0.00 |
DisclosureSEC source: 0001179110-10-004230 · edgar.xml · derivative · entry 8 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,855 Underlying: Common shares · 1,855 shares Expires 2014-02-19 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 01, 2010 Filed Mar 2, 2010 23:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 2,454 | $0.00 Strike: $41.03 | $0.00 |
DisclosureSEC source: 0001179110-10-004230 · edgar.xml · derivative · entry 7 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 2,454 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 01, 2010 Filed Mar 2, 2010 23:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,855 | $54.28 | $100,689.40 |
DisclosureSEC source: 0001179110-10-004230 · edgar.xml · nonDerivative · entry 3 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,599 Read SEC document |
| March 01, 2010 Filed Mar 2, 2010 23:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 2,454 | $41.03 | $100,691.79 |
DisclosureSEC source: 0001179110-10-004230 · edgar.xml · nonDerivative · entry 2 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,454 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2010 Filed Mar 2, 2010 23:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,851 | $54.12 | $479,016.12 |
DisclosureSEC source: 0001179110-10-004230 · edgar.xml · nonDerivative · entry 1 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Read SEC document |
| February 19, 2010 Filed Feb 24, 2010 01:46 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 28,700 | $0.00 Strike: $54.50 | $0.00 |
DisclosureSEC source: 0001179110-10-003587 · edgar.xml · derivative · entry 6 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,700 Underlying: Common shares · 28,700 shares Expires 2020-02-18 F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 9,567 on 2/19/2011, 9,566 on 2/19/2012, and 9,567 on 2/19/2013. Read SEC document |
| February 19, 2010 Filed Feb 24, 2010 01:46 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-003587 · edgar.xml · nonDerivative · entry 2 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,851 F2 · shares: These shares represent a retention award of restricted stock under the Abbott Laboratories 2009 Incentive Stock Program. The awards generally vest on the third anniversary of their grant date and include the right to have stock withheld for tax purposes. Read SEC document |
| February 19, 2010 Filed Feb 24, 2010 01:46 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 19,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-003587 · edgar.xml · nonDerivative · entry 1 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,851 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 22:58 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,035 | $53.93 | $271,537.55 |
DisclosureSEC source: 0001179110-10-003122 · edgar.xml · nonDerivative · entry 1 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,251 Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 11,261 | $0.00 Strike: $53.12 | $0.00 |
DisclosureSEC source: 0001179110-10-002720 · edgar.xml · derivative · entry 27 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 11,261 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 17,274 | $0.00 Strike: $52.66 | $0.00 |
DisclosureSEC source: 0001179110-10-002720 · edgar.xml · derivative · entry 26 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 17,274 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 9,686 | $0.00 Strike: $52.25 | $0.00 |
DisclosureSEC source: 0001179110-10-002720 · edgar.xml · derivative · entry 25 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 9,686 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $53.31 | $21,324.00 |
DisclosureSEC source: 0001179110-10-002720 · edgar.xml · nonDerivative · entry 21 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,286 Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,100 | $53.30 | $111,930.00 |
DisclosureSEC source: 0001179110-10-002720 · edgar.xml · nonDerivative · entry 20 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,686 Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,700 | $53.29 | $197,173.00 |
DisclosureSEC source: 0001179110-10-002720 · edgar.xml · nonDerivative · entry 19 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,786 Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,600 | $53.28 | $138,528.00 |
DisclosureSEC source: 0001179110-10-002720 · edgar.xml · nonDerivative · entry 18 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,486 Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,000 | $53.27 | $106,540.00 |
DisclosureSEC source: 0001179110-10-002720 · edgar.xml · nonDerivative · entry 17 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,086 Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $53.26 | $5,326.00 |
DisclosureSEC source: 0001179110-10-002720 · edgar.xml · nonDerivative · entry 16 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,086 Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,000 | $53.25 | $213,000.00 |
DisclosureSEC source: 0001179110-10-002720 · edgar.xml · nonDerivative · entry 15 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,186 Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,900 | $53.24 | $154,396.00 |
DisclosureSEC source: 0001179110-10-002720 · edgar.xml · nonDerivative · entry 14 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,186 Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 800 | $53.23 | $42,584.00 |
DisclosureSEC source: 0001179110-10-002720 · edgar.xml · nonDerivative · entry 13 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,086 Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,800 | $53.22 | $95,796.00 |
DisclosureSEC source: 0001179110-10-002720 · edgar.xml · nonDerivative · entry 12 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,886 Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 900 | $53.21 | $47,889.00 |
DisclosureSEC source: 0001179110-10-002720 · edgar.xml · nonDerivative · entry 11 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,686 Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,000 | $53.20 | $53,200.00 |
DisclosureSEC source: 0001179110-10-002720 · edgar.xml · nonDerivative · entry 10 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,586 Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $53.19 | $15,957.00 |
DisclosureSEC source: 0001179110-10-002720 · edgar.xml · nonDerivative · entry 9 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,586 Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $53.18 | $5,318.00 |
DisclosureSEC source: 0001179110-10-002720 · edgar.xml · nonDerivative · entry 8 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,886 Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $53.17 | $15,951.00 |
DisclosureSEC source: 0001179110-10-002720 · edgar.xml · nonDerivative · entry 7 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,986 Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,700 | $53.16 | $90,372.00 |
DisclosureSEC source: 0001179110-10-002720 · edgar.xml · nonDerivative · entry 6 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,286 Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,900 | $53.15 | $260,435.00 |
DisclosureSEC source: 0001179110-10-002720 · edgar.xml · nonDerivative · entry 5 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,986 Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 8,621 | $53.14 | $458,119.94 |
DisclosureSEC source: 0001179110-10-002720 · edgar.xml · nonDerivative · entry 4 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,886 Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 11,261 | $53.12 | $598,184.32 |
DisclosureSEC source: 0001179110-10-002720 · edgar.xml · nonDerivative · entry 3 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 17,274 | $52.66 | $909,648.84 |
DisclosureSEC source: 0001179110-10-002720 · edgar.xml · nonDerivative · entry 2 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 9,686 | $52.25 | $506,121.59 |
DisclosureSEC source: 0001179110-10-002720 · edgar.xml · nonDerivative · entry 1 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2009 Filed Jan 15, 2010 22:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 478 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-001169 · edgar.xml · nonDerivative · entry 4 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 1,088 F2 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his wife and daughter. Read SEC document |
| December 22, 2009 Filed Jan 15, 2010 22:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 478 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-001169 · edgar.xml · nonDerivative · entry 1 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,286 Read SEC document |
| December 18, 2009 Filed Dec 18, 2009 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 7,800 | $53.71 | $418,938.00 |
DisclosureSEC source: 0001179110-09-017237 · edgar.xml · nonDerivative · entry 1 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,764 Read SEC document |
| December 10, 2009 Filed Dec 11, 2009 22:50 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,000 | $53.80 | $269,000.00 |
DisclosureSEC source: 0001179110-09-016821 · edgar.xml · nonDerivative · entry 1 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,564 Read SEC document |
| April 24, 2009 Filed Apr 28, 2009 22:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,842 | $43.36 | $79,869.12 |
DisclosureSEC source: 0001104659-09-026803 · a4.xml · nonDerivative · entry 1 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,564 Read SEC document |
| February 27, 2009 Filed Mar 3, 2009 16:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,826 | $50.58 | $244,099.08 |
DisclosureSEC source: 0001104659-09-013731 · a4.xml · nonDerivative · entry 1 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,406 Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 38,700 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011815 · a4.xml · derivative · entry 5 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,700 Underlying: Common shares · 38,700 shares Expires 2019-02-19 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,900 on 02/20/2010, 12,900 on 02/20/2011, and 12,900 on 02/20/2012. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 27,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011815 · a4.xml · nonDerivative · entry 1 Chen Thomas F · CIK 0001360147 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,232 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.